Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 27.85
- Piotroski Score 6.00
- Grade Outperform
- Symbol (INBX)
- Company Inhibrx Biosciences, Inc.
- Price $14.24
- Changes Percentage (1.86%)
- Change $0.26
- Day Low $13.87
- Day High $14.28
- Year High $18.95
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
- Last Earnings N/A
- Ex-Dividend for 5/16 Dividend 05/30/2024
- Dividend Payable 06/20/2024
- Today N/A
- Next Earnings (Estimated) 02/13/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$11.56
- Trailing P/E Ratio -1.44
- Forward P/E Ratio -1.44
- P/E Growth -1.44
- Net Income $-241,361,000
Income Statement
Quarterly
Annual
Latest News of INBX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
The recent drop in prices must have disappointed Inhibrx Biosciences, Inc. (NASDAQ:INBX) institutional investors who own 43% of the shares
Inhibrx Biosciences has 7 investors with a majority stake of 50%. Institutions hold 43% ownership, facing the biggest gain or loss. Hedge funds and individuals also hold significant stakes, with Vikin...
By Yahoo! Finance | 5 days ago -
Director Kristiina Vuori Purchases Shares of Inhibrx Biosciences Inc (INBX)
Inhibrx Biosciences Inc (NASDAQ:INBX) is a biotech company developing therapeutic candidates for various medical needs. Recent insider transactions show more buying than selling, indicating confidence...
By Yahoo! Finance | 2 months ago
